Summary:
- Alnylam Pharmaceuticals, a leading biopharmaceutical company, has announced preliminary fourth-quarter and full-year 2024 global net product revenues, as well as provided guidance for 2025 combined net product revenues and pipeline goals.
- The company's preliminary global net product revenues for the fourth quarter of 2024 are expected to be between $1.2 billion and $1.3 billion, and for the full year 2024, between $4.4 billion and $4.5 billion.
- Alnylam has also provided guidance for 2025 combined net product revenues to be in the range of $5.2 billion to $5.6 billion, and has outlined several pipeline goals for the coming year, including the advancement of its late-stage clinical programs and the expansion of its portfolio.